AbbVie (ABBV) has a solid estimated long-term growth rate of 16% a year, a 4% yield, and a 13 P/E. So why is this stock so cheap?
Fears of an expiring patent on its top drug and weak data on a new drug are holding back shares of AbbVie (ABBV).
Shares of AbbVie (ABBV) aren’t moving higher because it’s biggest drug Humira could lose patent protection in the coming years.
Shares of AbbVie (ABBV) are an extreme value and this biopharmaceutical company is on my radar.